Determining clinically meaningful decline in preclinical Alzheimer disease

OBJECTIVE: To determine the time required for a preclinical Alzheimer disease population to decline in a meaningful way, use estimates of decline to update previous clinical trial design assumptions, and identify factors that modify β-amyloid (Aβ)–related decline. METHODS: In 1,120 cognitively unimp...

Descripción completa

Detalles Bibliográficos
Autores principales: Insel, Philip S., Weiner, Michael, Mackin, R. Scott, Mormino, Elizabeth, Lim, Yen Ying, Stomrud, Erik, Palmqvist, Sebastian, Masters, Colin L., Maruff, Paul T., Hansson, Oskar, Mattsson, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669933/
https://www.ncbi.nlm.nih.gov/pubmed/31289148
http://dx.doi.org/10.1212/WNL.0000000000007831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669933/
https://www.ncbi.nlm.nih.gov/pubmed/31289148
http://dx.doi.org/10.1212/WNL.0000000000007831

Ejemplares similares